Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s Mindray Expands Market With Increased R&D And Acquisitions

This article was originally published in PharmAsia News

Executive Summary

Mindray expects to hold its own amidst foreign competition, including in the high-end device market thanks to acquisitions and R&D investments that have boosted its technological capability.

You may also be interested in...

China's Top Device Maker Mindray Enters Critical Care Market; Sees Boosts From Color Ultrasound Devices

Despite a negative impact from political unrest in the Middle East, China's leading medical device maker Mindray Medical International is steaming ahead with solid first quarter growth in both international and Chinese domestic markets. That growth was driven largely by a continued stronghold in its low- to mid-end device market, as well as an emerging footprint in the lucrative high-end segment with its color ultrasound devices

China's Mindray Sees Growth In Emerging Markets, But Looks To Jump-start Stagnant Sales At Home

SHANGHAI - China's leading medical device company Mindray's third quarter report disappointed investors again with an 11.3% increase in revenue over the same period last year to $168 million, which missed Street expectations of $170-178 million. Weak sales in China are the culprit for slow growth, even as the company sees significant gains in other emerging markets

China's Leading Medical Equipment Maker Succeeds - Where Others Stumble - In Merging With U.S. Competitor

BEIJING - China's leading developer of medical devices, Mindray Medical International, is emerging as the golden success story in terms of a Chinese enterprise taking over an American competitor in the life sciences arena, with a 15.8 percent jump in net revenues for 2009 to $634.2 million


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts